{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-26-000043","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-07-22T21:03:59+00:00","discovered_at":"2026-07-22T21:06:00.316077+00:00","generated_at":"2026-07-22T21:06:06.667084+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Serina Therapeutics appoints Farrell Simon to Board of Directors","bullets":["Farrell Simon appointed to Serina's Board effective July 22, 2026; will serve on Audit and Compensation Committees.","Simon is Chief Commercial Officer at Trevi Therapeutics (TRVI), helped raise over $400M from top-tier investors.","Previously spent a decade at Pfizer in senior commercial and strategic roles.","Serina's SER-252 Phase 1b registrational study is double-blind, placebo-controlled, with single and multiple ascending doses in Parkinson's patients.","Simon's experience in commercial strategy and business development expected to support Serina's POZ platform and SER-252 development."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-26-000043","json":"https://secwatch.observer/filing/0001708599-26-000043.json","markdown":"https://secwatch.observer/filing/0001708599-26-000043.md","text":"https://secwatch.observer/filing/0001708599-26-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000043/0001708599-26-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000043/ser-20260723xappointmentof.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-22T21:06:06.667084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f48f7eb255","claim":"Farrell Simon was appointed as Member of the Board of Directors at Serina Therapeutics, Inc..","evidence_excerpt":"On July 22, 2026, Serina Therapeutics, Inc. (the “Company”) issued a press release announcing the appointment of Farrell Simon, Pharm. D., to the Company’s Board of Directors, effective July 22, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000043/0001708599-26-000043-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}